CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

CIDP causes muscle weakness and numbness, among other symptoms. Diagnosing CIDP involves peripheral nervous system testing, cerebrospinal fluid analysis, and imaging. CIDP is an immune-mediated ...

In a statement, Argenx said that the subcutaneously administered drug is the first “meaningful” new treatment option for the approximately 24,000 people living with CIDP in the US in more than ...

Your treatment will depend on what’s causing ... Chronic inflammatory demyelinating polyneuropathy (CIDP). Treatments are very specialized and include plasma exchange (plasmapheresis) or ...

The American Academy of Family Physicians recommends that peripheral neuropathy treatment address the underlying disease process, correct nutritional deficiencies, and aim to provide relief from ...

Phase 4 switch study ongoing in CIDP to inform treatment decisions when switching a patient on IVIg to VYVGART SC ADVANCE-NEXT confirmatory study ongoing of VYVGART IV in primary ITP to support ...

Phase 4 switch study ongoing in CIDP to inform treatment decisions when switching a patient on IVIg to VYVGART SC ADVANCE-NEXT confirmatory study ongoing of VYVGART IV in primary ITP to support FDA ...